STIM 📈 Analysis and forecast of the company's shares 📉 Neuronetics, Inc.

The company's share price Neuronetics, Inc.

Neuronetics produces transcranial magnetic stimulation (TMS) systems for the treatment of depression. Its stock price reflects its efforts to expand the use of this non-invasive therapy. The chart tells the story of its struggle for recognition from doctors and insurance companies.

Share prices of companies in the market segment - Specialized medical equipment

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive treatment for depression using transcranial magnetic stimulation. We've classified it as "Specialized Medical Equipment." The chart below shows how the market is evaluating new mental health technologies.

Broad Market Index - GURU.Markets

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive treatment for depression using transcranial magnetic stimulation. It is included in the GURU.Markets index. The chart below shows the market. See how this company's stock compares to the medical device sector.

STIM - Daily change in the company's share price Neuronetics, Inc.

For Neuronetics, a manufacturer of depression treatment devices, change_co is a measure of its response to changes in healthcare. Daily fluctuations reflect sensitivity to tariffs and competition. This metric is important for analyzing volatility in the medical device sector on System.GURU.Markets.

Daily change in the price of a set of shares in a market segment - Specialized medical equipment

Neuronetics, Inc. is a medical device company. This chart illustrates the high volatility of the MedTech industry. Comparing it to STIM, which focuses on depression treatment, helps us understand how its innovative products contribute to its volatility.

Daily change in the price of a broad market stock, index - GURU.Markets

Neuronetics produces non-invasive brain stimulation systems for the treatment of depression. It is an innovative medtech company whose stock price is driven by the adoption of its technology by doctors and patients. Its history reflects the medtech sector's contribution to overall market volatility.

Annual dynamics of the company's market capitalization Neuronetics, Inc.

Neuronetics, Inc.'s year-over-year performance is a story about the commercialization of its NeuroStar system for treating depression. Its 12-month market cap growth reflects the growing number of psychiatric clinics using its transcranial magnetic stimulation (TMS) technology and expanded insurance coverage for this drug-free therapy.

Annual dynamics of market capitalization of the market segment - Specialized medical equipment

Neuronetics, Inc. is a medical device company that has developed a non-invasive neurostimulation technology for the treatment of depression. This chart shows how its efforts to commercialize this innovative therapy and competition from traditional treatments are impacting its performance in the sector.

Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets

Neuronetics, with its system for treating depression, is a growth story in medicine. Its stock price is determined not by the economy, but by the speed of adoption by doctors and the insurance system. The chart reflects the potential of this breakthrough technology in the vast mental health market, regardless of the state of the economy.

Monthly dynamics of the company's market capitalization Neuronetics, Inc.

Neuronetics, a medical device manufacturer, is valued based on the adoption of its technology. The monthly fluctuations in the chart reflect the growing number of installations of its NeuroStar systems for treating depression using transcranial magnetic stimulation.

Monthly dynamics of market capitalization of the market segment - Specialized medical equipment

Neuronetics produces non-invasive brain stimulation systems used to treat depression. The mental health medical device sector is growing amid the search for alternatives to traditional drug therapy. Industry dynamics reflect the market and the medical community's readiness to embrace new technologies to address complex mental health issues.

Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets

Neuronetics, Inc. has developed and commercialized the NeuroStar Advanced Therapy system—a noninvasive treatment for depression using transcranial magnetic stimulation (TMS). Its business depends on physician acceptance of the technology. The broader market chart provides a backdrop for assessing the market penetration of its innovative therapy as an alternative to antidepressants.

Weekly dynamics of the company's market capitalization Neuronetics, Inc.

Neuronetics, Inc. has developed the NeuroStar Advanced Therapy system—a non-invasive treatment for depression using transcranial magnetic stimulation. Its weekly stock price is dependent on the pace of adoption of this technology and the decisions of insurance companies.

Weekly dynamics of market capitalization of the market segment - Specialized medical equipment

Neuronetics produces non-invasive brain stimulation equipment for the treatment of depression. Demand for its products depends on the acceptance of the technology by doctors and insurance companies. The chart below shows how Neuronetics' stock performance differs from the medical equipment sector, driven by unique growth drivers.

Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets

Neuronetics produces medical equipment for the treatment of depression. It's a rapid growth story in the medical industry. The chart below shows how its shares, driven by the introduction of new technology, are more volatile and outperform the broader market, reflecting investor confidence in its potential.

STIM - Market capitalization of the company Neuronetics, Inc.

Neuronetics' market capitalization reflects its position in the market for noninvasive depression treatments using its NeuroStar system. Its market cap chart shows how investors view its efforts to expand the use of this technology. This is a bet that transcranial magnetic stimulation will become a standard treatment.

STIM - Share of the company's market capitalization Neuronetics, Inc. within the market segment - Specialized medical equipment

Neuronetics is a pioneer and leader in transcranial magnetic stimulation (TMS) for the treatment of depression. Its dominant market share in this niche is reflected by its NeuroStar technology. The chart shows the company's market share, which offers a non-drug approach to treating one of the most common mental disorders.

Market capitalization of the market segment - Specialized medical equipment

The graph below shows the total value of the medical device sector. Neuronetics is a pioneer and leader in transcranial magnetic stimulation (TMS) for the treatment of depression. The growth of this market, which you see, reflects the search for alternatives to drug treatment. Neuronetics offers a non-invasive and technologically advanced approach to solving this serious problem.

Market capitalization of all companies included in a broad market index - GURU.Markets

Neuronetics produces the NeuroStar non-invasive brain stimulation system for the treatment of depression. Its market capitalization reflects the demand for alternative treatments for mental disorders. The chart below shows the economic weight of neuromodulation equipment manufacturers.

STIM - Book value capitalization of the company Neuronetics, Inc.

Neuronetics' book value is derived from its manufacturing capacity for NeuroStar transcranial magnetic stimulation (TMS) systems for treating depression. The chart shows how the pioneer in this field is investing in the commercialization and expansion of its non-invasive therapeutic technology.

STIM - Share of the company's book capitalization Neuronetics, Inc. within the market segment - Specialized medical equipment

Neuronetics has developed a non-invasive therapy for depression. The chart shows its share of real assets. These are its manufacturing facilities, where NeuroStar devices, the physical embodiment of its transcranial magnetic stimulation technology, are assembled.

Market segment balance sheet capitalization - Specialized medical equipment

Neuronetics produces equipment for treating depression. This business requires investment in R&D and production, making it capital-intensive. The chart below shows the total asset value of the medical device sector, providing a basis for assessing its base.

Book value of all companies included in the broad market index - GURU.Markets

Neuronetics is a pioneer in transcranial magnetic stimulation (TMS) for the treatment of depression. The company's assets include the production of NeuroStar systems. Its stake in BCap_All represents the company's ability to produce non-invasive medical equipment offering an alternative to drug treatment.

Market capitalization to book capitalization ratio - Neuronetics, Inc.

Neuronetics is a medical device manufacturer. Its assets are being boosted by the evaluation of its transcranial magnetic stimulation (TMS) technology for the treatment of depression and its potential for expansion to other mental disorders.

Market to book capitalization ratio in a market segment - Specialized medical equipment

Neuronetics produces the NeuroStar system for the non-invasive treatment of depression. This figure reflects the premium the market places on its patented technology and market position in alternative mental health treatments, over and above the value of its manufacturing assets.

Market to book capitalization ratio for the market as a whole

Neuronetics produces the NeuroStar system for non-invasive brain stimulation to treat depression. It's a medical technology company with a patented product. This chart helps us estimate the market premium for innovative treatments that can change patients' lives, above and beyond the cost of physical assets.

STIM - Company debts Neuronetics, Inc.

Neuronetics, Inc., a company that developed neurostimulation technology for the treatment of depression, is using debt to commercialize its Neurostar product. The capital is being used to expand the sales team, market to physicians and patients, and research into applying the technology to other conditions, which requires significant investment for market penetration.

Market segment debts - Specialized medical equipment

Neuronetics produces non-invasive brain stimulation systems (NeuroStar) for the treatment of depression. In the specialized medical device sector, debt can be used to fund clinical trials to expand indications, as well as for marketing. This chart shows how aggressively the company is marketing its technology.

Market debt in general

The company's debt to book capitalization ratio Neuronetics, Inc.

Neuronetics produces non-invasive brain stimulation systems for the treatment of depression. Commercializing such complex medical equipment requires significant marketing and physician training expenditures. This chart shows the extent to which the company uses debt to market its technology and helps assess the risks associated with the return on this investment.

Market segment debt to market segment book capitalization - Specialized medical equipment

Neuronetics is the manufacturer of the NeuroStar Advanced Therapy system, a non-invasive treatment for depression using transcranial magnetic stimulation. This chart shows debt trends in the medical device sector. It helps assess how the company is financing the commercialization of its unique technology and how its debt strategy compares to other innovators.

Debt to book value of all companies in the market

Neuronetics produces non-invasive brain stimulation systems for the treatment of depression. This is an innovative medical technology that requires investment in marketing and further research. This chart shows the general trend in the debt market. It allows us to assess Neuronetics' strategy: whether it finances its growth through profits and shareholders or actively pursues debt, like many other companies.

P/E - Neuronetics, Inc.

Neuronetics is the manufacturer of the NeuroStar Advanced Therapy medical system used to treat major depressive disorder. This chart shows how the market assesses the commercial potential of its non-drug treatment. This assessment depends on the pace of adoption of this technology in psychiatric practice and the expansion of insurance coverage.

P/E of the market segment - Specialized medical equipment

This chart shows the average rating for medical device manufacturers where Neuronetics operates. It reflects overall expectations for the sector. Comparisons help understand whether Neuronetics' unique technology (transcranial magnetic stimulation for the treatment of depression) is viewed as more or less promising than companies with other treatment methods.

P/E of the market as a whole

Neuronetics is the maker of the NeuroStar system for non-invasive brain stimulation, used to treat depression. The company's growth depends on expanding insurance coverage and physician acceptance of the technology. This chart of overall sentiment in the medtech sector helps understand how investors value companies creating new markets for innovative treatments.

Future (projected) P/E of the company Neuronetics, Inc.

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive device for the treatment of major depressive disorder using transcranial magnetic stimulation (TMS). This graph reflects the expected growth of the non-drug depression treatment market. This estimate depends on expanded insurance coverage and the acceptance of TMS as an effective alternative.

Future (projected) P/E of the market segment - Specialized medical equipment

Neuronetics is the manufacturer of the NeuroStar Advanced Therapy system, a non-invasive treatment for depression using transcranial magnetic stimulation. This chart shows the company's estimated future revenue in the context of the medical device sector. It demonstrates how much investors believe this alternative therapy will gain traction.

Future (projected) P/E of the market as a whole

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive treatment for major depressive disorder using transcranial magnetic stimulation (TMS). This graph of overall market sentiment for STIM is important in the context of healthcare costs. Demand for their innovative, yet expensive, therapy depends on insurance coverage and clinics' willingness to invest.

Company profit Neuronetics, Inc.

Neuronetics produces the NeuroStar Advanced Therapy system—a non-invasive treatment for major depressive disorder using transcranial magnetic stimulation (TMS). This chart shows how successfully the company is promoting its technology as an alternative to traditional depression treatments.

Profit of companies in the market segment - Specialized medical equipment

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive treatment for depression using transcranial magnetic stimulation (TMS). This chart shows profitability in the medical device sector. For STIM, this reflects the growing demand for alternative treatments for mental disorders, an important and growing area of ​​healthcare.

Overall market profit

Neuronetics is the manufacturer of the NeuroStar Advanced Therapy medical system, a non-invasive treatment for depression using transcranial magnetic stimulation (TMS). The company's growth depends on wider acceptance of this method by physicians and insurance companies. This graph of overall corporate profitability does not reflect the specifics of the medical device market.

Future (projected) profit of the company Neuronetics, Inc.

Neuronetics is a pioneer in transcranial magnetic stimulation (TMS) for the treatment of depression through its NeuroStar system. The revenue forecast presented here reflects expectations for increased adoption of this drug-free therapy. Increasing the number of installed systems and their usage are key drivers for the company.

Future (predicted) profit of companies in the market segment - Specialized medical equipment

Neuronetics produces the NeuroStar transcranial magnetic stimulation (TMS) system, a non-drug treatment for depression. Profit projections for this sector depend on the acceptance of the technology by insurance companies and patients. This chart shows analysts' expectations for the growth of the alternative mental health treatment market.

Future (predicted) profit of the market as a whole

Neuronetics produces a non-invasive brain stimulation system for the treatment of depression. Demand for its products depends on technology acceptance and insurance coverage. The overall economic forecasts shown in this chart may impact healthcare budgets and the willingness of payers to cover innovative treatments.

P/S - Neuronetics, Inc.

Neuronetics produces the NeuroStar Advanced Therapy system for non-invasive brain stimulation to treat depression. This chart shows how the market estimates revenue from sales of this innovative medical system. This estimate depends on expanding insurance coverage and the company's ability to expand its market penetration in mental health treatments.

P/S market segment - Specialized medical equipment

Neuronetics is a pioneer in transcranial magnetic stimulation (TMS) for the treatment of depression through its NeuroStar system. It is a non-invasive alternative to drug treatment. This chart shows the average revenue estimate for the medical device sector, helping to understand how the market views Neuronetics' innovative technology and market position.

P/S of the market as a whole

Neuronetics is a pioneer in transcranial magnetic stimulation (TMS), a non-drug treatment for major depressive disorder. The company's growth depends on the distribution of its NeuroStar system. This chart provides a market-wide perspective for investors on revenue prospects in the innovative medical device sector.

Future (projected) P/S of the company Neuronetics, Inc.

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive device for treating major depressive disorder using transcranial magnetic stimulation (TMS). This chart shows how investors estimate the company's future sales, reflecting the demand for alternative depression treatments.

Future (projected) P/S of the market segment - Specialized medical equipment

Neuronetics, Inc. produces the NeuroStar Advanced Therapy system for the non-invasive treatment of major depressive disorder using transcranial magnetic stimulation (TMS). This chart shows how investors view its technology as an alternative to medication and its potential for penetration into the mental health market.

Future (projected) P/S of the market as a whole

Neuronetics produces the NeuroStar system for non-invasive brain stimulation, used to treat depression. Demand for their equipment depends on the acceptance of the method and insurance coverage. This schedule, reflecting economic stability, is important for STIM. It ensures sustainable funding for the healthcare system, allowing clinics to invest in new equipment.

Company sales Neuronetics, Inc.

Neuronetics is a pioneer in the non-drug treatment of depression. The company produces the NeuroStar Advanced Therapy system, which uses transcranial magnetic stimulation (TMS). This chart shows sales of the system to clinics and revenue from treatments performed. Growing sales demonstrate the growing acceptance of this innovative method in psychiatry.

Sales of companies in the market segment - Specialized medical equipment

Neuronetics is a pioneer in non-drug treatments for depression. Their NeuroStar Advanced Therapy system uses transcranial magnetic stimulation (TMS) to help patients who have not responded to antidepressants. This chart shows how their revenue is split between sales of the systems themselves and the disposable components required for each treatment.

Overall market sales

Neuronetics is a pioneer in transcranial magnetic stimulation (TMS) for the treatment of depression. Its NeuroStar system offers a drug-free therapy option for patients who have not responded to antidepressants. This revenue chart includes the healthcare sector, where TMS offers an innovative solution to one of the most common mental health problems.

Future (projected) sales of the company Neuronetics, Inc.

Neuronetics produces the NeuroStar Advanced Therapy system, a non-drug treatment for major depressive disorder using transcranial magnetic stimulation (TMS). This graph reflects analysts' expectations for the growing adoption of TMS therapy as an alternative to antidepressants.

Future (projected) sales of companies in the market segment - Specialized medical equipment

Neuronetics is a pioneer in non-invasive neurostimulation, producing the NeuroStar system for the treatment of depression. This chart shows forecasts for the entire neuromodulation device market. It reflects the growing demand for alternative, non-drug treatments for mental disorders, where Neuronetics holds a leading position.

Future (projected) sales of the market as a whole

Neuronetics, Inc., the developer of a non-invasive therapy for depression (NeuroStar), sees this chart as a reflection of the state of the healthcare system. Rising overall economic forecasts ensure stable insurance coverage, making advanced mental health treatments, such as transcranial magnetic stimulation, more accessible to patients.

Company marginality Neuronetics, Inc.

Neuronetics produces the Neurostar Advanced Therapy system, a non-invasive treatment for major depressive disorder. The company's profitability depends on sales of this specialized medical device. This chart shows how successfully Neuronetics is commercializing its technology and managing production and marketing costs.

Market segment marginality - Specialized medical equipment

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive treatment for depression using transcranial magnetic stimulation. This chart shows the company's success in commercializing its technology. This high score indicates clinical effectiveness and growing acceptance of this treatment method.

Market marginality as a whole

#VALUE!

Number of employees in the company Neuronetics, Inc.

Neuronetics is a pioneer in non-invasive neurostimulation for the treatment of mental disorders. Its NeuroStar system uses transcranial magnetic stimulation (TMS) to treat depression. This graphic shows the team that produces and markets this equipment, offering an alternative for patients who are not responding to antidepressants.

Share of the company's employees Neuronetics, Inc. within the market segment - Specialized medical equipment

Neuronetics, Inc. has developed NeuroStar, a non-invasive transcranial magnetic stimulation (TMS) system for the treatment of depression. Promoting and supporting such an innovative medical technology requires a large team of clinical specialists and engineers. This chart illustrates how the company is changing approaches to treating mental disorders by consolidating talent in this niche.

Number of employees in the market segment - Specialized medical equipment

Neuronetics is the manufacturer of NeuroStar, a transcranial magnetic stimulation (TMS) system—a non-invasive treatment for depression in patients who are not responding to antidepressants. This graphic shows the team of engineers and clinicians who are offering an alternative for the millions of people suffering from severe depression.

Number of employees in the market as a whole

Neuronetics, Inc. developed NeuroStar, a non-invasive therapy for depression. The labor market situation, shown in this graph, indirectly impacts their business. Economic stability and widespread insurance coverage associated with high employment rates make innovative treatments like NeuroStar more accessible to patients in need.

Market capitalization per employee (in thousands of dollars) of the company Neuronetics, Inc. (STIM)

Neuronetics, Inc. has developed a non-invasive brain stimulation system for treating depression. This chart illustrates the model of a company manufacturing complex medical equipment. The capitalization per employee ratio reflects the balance between the high cost of technology (IP) and the need to maintain staff for production, sales, and physician training.

Market capitalization per employee (in thousands of dollars) in the market segment - Specialized medical equipment

Neuronetics is a leader in non-invasive neurostimulation for the treatment of depression using the NeuroStar system. In the specialized medical device sector, value is determined by the uniqueness of its technology. This chart shows how the market values ​​its patents and market position per employee compared to other medtech companies.

Market capitalization per employee (in thousands of dollars) for the overall market

Neuronetics produces the NeuroStar Advanced Therapy system—a non-invasive treatment for major depressive disorder using transcranial magnetic stimulation (TMS). This indicator reflects the value of its unique technology and demonstrates how the company creates value by offering an alternative to drug-based treatments for mental illness.

Profit per employee (in thousands of dollars) of the company Neuronetics, Inc. (STIM)

Neuronetics is the medical company behind the NeuroStar system, which uses transmagnetic stimulation (TMS) to treat depression. This chart illustrates their "razor and blades" model. They sell the equipment and then generate recurring revenue from the sale of consumables for each treatment. This model ensures growing profitability.

Profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment

Neuronetics is the manufacturer of NeuroStar Advanced Therapy, a non-invasive transcranial magnetic stimulation (TMS) system for the treatment of major depressive disorder. This chart represents an industry benchmark. In the specialized medical device sector, it reflects how effectively Neuronetics manages the production and, more importantly, the commercialization (sales) of its expensive system to clinics.

Profit per employee (in thousands of dollars) for the market as a whole

Neuronetics produces the NeuroStar Advanced Therapy system, a non-invasive TMS (transcranial magnetic stimulation) treatment for depression. It's a "razor and blade" model. They sell an expensive device (the "razor") and, more importantly, disposable kits for each treatment. This graph shows how successfully their sales team is growing the installed base of devices, leading to increased profits from consumables.

Sales per company employee Neuronetics, Inc. (STIM)

Neuronetics produces the NeuroStar Advanced Therapy system for the treatment of depression using transcranial magnetic stimulation. This graph shows its performance in the medical device niche. The increase in revenue per employee reflects the increase in the number of systems installed in clinics and increased revenue from the sale of disposable components for procedures.

Sales per employee in the market segment - Specialized medical equipment

Neuronetics (STIM) produces the NeuroStar transcranial magnetic stimulation (TMS) system for the treatment of depression. It operates on a "razor and blades" model, selling equipment and consumables. This chart shows how effective their model (R&D, manufacturing, and sales to clinics) is in generating revenue per employee compared to other medical device manufacturers.

Sales per employee for the market as a whole

Neuronetics is the company behind the NeuroStar system, a noninvasive magnetic stimulation (TMS) technology that uses magnetic pulses to treat depression. Their business operates on a "razor and blades" model: they sell or lease the devices, and their primary revenue comes from recurring treatment sessions. This chart shows the revenue generated by this model.

Shares shorted by company Neuronetics, Inc. (STIM)

Neuronetics (STIM) produces NeuroStar, a transcranial magnetic stimulation (TMS) system for the treatment of major depressive disorder (MDD) in patients who are unresponsive to medication. This chart measures bearish bets. The rise in shorts may reflect concerns about the slow adoption of their expensive technology by clinics or issues with insurance coverage.

Shares shorted by market segment - Specialized medical equipment

Neuronetics (STIM) has developed NeuroStar, a transmagnetic stimulation (TMS) system for the treatment of major depressive disorder in patients who have not responded to medication. This chart illustrates the overall sentiment in the medical device sector, showing how many investors are hesitant about the widespread adoption of this technology.

Shares shorted by the overall market

Neuronetics produces NeuroStar, a drug-free treatment for depression. Mental health is a critical need. However, this is capital equipment sold to clinics. High market fears (as shown in this chart) may force clinics to postpone major purchases, even essential equipment, to conserve cash.

The company's RSI 14 indicator Neuronetics, Inc. (STIM)

Neuronetics (STIM) is a medical device company. Their NeuroStar Advanced Therapy system is a non-invasive transmagnetic stimulation (TMS) treatment for depression. This chart measures momentum. It shows "overheated" (above 70) amid growing installations of their systems in clinics, or "oversold" (below 30) amid intense competition.

RSI 14 Market Segment - Specialized medical equipment

Neuronetics (STIM) is behind the NeuroStar system. This transcranial magnetic stimulation (TMS) device is a non-invasive treatment for depression for patients who are not responding to medications. This chart tracks the pulse of the Specialized Medical Equipment sector. It helps differentiate STIM's commercial success from the overall "overheated" or "oversold" medtech sector.

RSI 14 for the overall market

Neuronetics (STIM) produces equipment for non-invasive brain stimulation (for depression treatment). This graph is an indicator of scheduled procedures. In a euphoric mood, people are ready to undergo expensive scheduled procedures. In a panic, fearing loss of insurance, patients may postpone "non-urgent" appointments.

Analyst consensus stock price forecast STIM (Neuronetics, Inc.)

Neuronetics is the medical technology company behind the NeuroStar system. This system uses transmagnetic stimulation (TMS) to treat major depressive disorder in patients who have not responded to medication. This chart shows analysts' 12-month target price based on the rate of adoption of this therapy.

The difference between the consensus estimate and the actual stock price STIM (Neuronetics, Inc.)

Neuronetics is the medical technology company behind the NeuroStar system. It's a transcranial magnetic stimulation (TMS) device—a non-invasive (drug-free) therapy used by psychiatrists to treat severe depression. This chart shows how confident analysts are in their ability to convince doctors and insurance companies of the effectiveness of this therapy.

Analyst consensus forecast for stock prices by market segment - Specialized medical equipment

Neuronetics (STIM) is the company behind the NeuroStar system, a brain magnetic stimulation (TMS) treatment for drug-resistant depression. This chart shows general expectations for the specialized medical equipment sector. It reflects whether experts believe there will be a growing demand for non-drug treatments in psychiatry.

Analysts' consensus forecast for the overall market share price

Neuronetics is the medical company behind the NeuroStar system, a non-invasive transcranial magnetic stimulation (TMS) treatment for depression in patients unresponsive to medication. This chart shows overall market sentiment. For Neuronetics, whose business is selling expensive equipment, the overall optimism is important because it reflects clinics' willingness to invest in new technologies.

AKiMA Company Index Neuronetics, Inc.

Neuronetics is the creator of NeuroStar, a leader in TMS therapy. It's a non-invasive system that uses magnetic pulses to stimulate the brain and treat depression in patients who haven't responded to medication. This chart shows their razor and blade performance. It reflects their ability to sell razors (the devices) and their growing, high-margin blade revenue for each treatment.

AKIMA Market Segment Index - Specialized medical equipment

Neuronetics is the medical company behind the NeuroStar Advanced Therapy system, a non-invasive transcranial magnetic stimulation (TMS) treatment for depression. This chart shows the average index for the specialized medical equipment sector. It helps assess how Neuronetics' technology compares to the industry average.

The AKIM Index for the overall market

Neuronetics is a medtech company that sells transcranial magnetic stimulation systems (NeuroStar) for the treatment of depression. This chart, which reflects the market average, is a backdrop. It helps assess how this drug alternative, dependent on patient costs and insurance, compares to overall macroeconomic trends.